Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
2.900
+0.080 (2.84%)
At close: Jun 23, 2026, 4:00 PM EDT
2.760
-0.140 (-4.83%)
After-hours: Jun 23, 2026, 4:48 PM EDT
Cellectis Employees
As of December 31, 2025, Cellectis had 229 total employees, including 224 full-time and 5 part-time employees. The number of employees increased by 7 or 3.15% compared to the previous year.
Employees
229
Change (1Y)
7
Growth (1Y)
3.15%
Revenue / Employee
$328,000
Profits / Employee
-$293,581
Market Cap
207.27M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 229 | 7 | 3.15% | 224 | 5 |
| Dec 31, 2024 | 222 | 1 | 0.45% | 216 | 6 |
| Dec 31, 2023 | 221 | -16 | -6.75% | 216 | 5 |
| Dec 31, 2022 | 237 | -63 | -21.00% | 231 | 6 |
| Dec 31, 2021 | 300 | 19 | 6.76% | 294 | 6 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| ProQR Therapeutics | 187 |
| Arcturus Therapeutics Holdings | 111 |
| Nkarta | 108 |
| Alector | 103 |
| Immunic | 95 |
| Compugen | 75 |
| Korro Bio | 49 |
CLLS News
- 13 days ago - Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress - GlobeNewsWire
- 13 days ago - Cellectis (CLLS) Receives FDA RMAT Designation for CAR-T Therapy, Shares Rise - GuruFocus
- 14 days ago - Cellectis (CLLS) Achieves RMAT Designation for CAR-T Therapy - GuruFocus
- 14 days ago - Cellectis granted RMAT designation for lasmecabtagene timgedleucel from FDA - TheFly
- 14 days ago - Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL - GlobeNewsWire
- 20 days ago - Monthly information on share capital and company voting rights - GlobeNewsWire
- 26 days ago - Cellectis initiated with an Overweight at Barclays - TheFly
- 4 weeks ago - Cellectis Slides: Corporate presentation - Filings